Use of Names. Except as otherwise provided in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the consent of such other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that either Party may use the name of the other Party in any document required to be filed to obtain Regulatory Approval or to comply with applicable laws, rules or regulations.
Appears in 9 contracts
Sources: License Agreement, License Agreement (Acorda Therapeutics Inc), License Agreement (ARCA Biopharma, Inc.)
Use of Names. Except as otherwise provided in this Agreement, neither Neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that either Party may use the name of the other Party in any document required to be filed to obtain Regulatory Approval with any regulatory agency or to comply with applicable lawsauthority, rules or regulationsincluding the FDA and the Securities and Exchange Commission.
Appears in 6 contracts
Sources: Collaboration Agreement (Shire Pharmaceuticals Group PLC), Row Territory License Agreement (New River Pharmaceuticals Inc), Row Territory License Agreement (Shire Pharmaceuticals Group PLC)
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld or delayedwithheld; provided, however, that subject to Section 12.5, either Party may use the name of the other Party in any document required to be filed to obtain with any Regulatory Approval Authority or to comply with applicable lawsGovernmental Authority, rules or regulationsincluding the Securities and Exchange Commission.
Appears in 5 contracts
Sources: Development, Commercialization and Supply Agreement (Amarin Corp Plc\uk), License Agreement (Onyx Pharmaceuticals Inc), Collaboration Agreement (Auxilium Pharmaceuticals Inc)
Use of Names. Except as otherwise provided in this Agreement, neither Party shall not use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the consent of such the other Party, Party (which consent shall not be unreasonably withheld or delayed; provided), however, that either Party except as may use the name of the other Party in any document be required to be filed to obtain Regulatory Approval or to comply with by applicable laws, rules or regulationslaw.
Appears in 5 contracts
Sources: License Agreement (Acorda Therapeutics Inc), License Agreement (Acorda Therapeutics Inc), License Agreement (Acorda Therapeutics Inc)
Use of Names. Except as otherwise provided in required by law or by the terms of this Agreement or the License Agreement, or as mutually agreed upon by the Parties, neither Party shall make any use of the name of the other Party in relation to this transaction in any public announcementadvertising or promotional material, press release or other public document otherwise, without the prior written consent of such the other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that either Party may use the name of the other Party in any document required to be filed to obtain Regulatory Approval or to comply with applicable laws, rules or regulationswithheld.
Appears in 5 contracts
Sources: Commercial Supply Agreement (Petros Pharmaceuticals, Inc.), Commercial Supply Agreement (Vivus Inc), License and Commercialization Agreement (Vivus Inc)
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld or delayedwithheld; provided, however, that subject to Section 11.4, either Party may use the name of the other Party in any document required to be filed to obtain with any Regulatory Approval Authority or to comply with applicable lawsGovernmental Authority, rules or regulationsincluding the Securities and Exchange Commission.
Appears in 5 contracts
Sources: License, Development and Commercialization Agreement (Zura Bio LTD), License, Development and Commercialization Agreement (JATT Acquisition Corp), License, Development and Commercialization Agreement (JATT Acquisition Corp)
Use of Names. Except as otherwise provided required by law or in this Agreementfurtherance of the exercise of its rights hereunder, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document related to this Agreement or the understanding reflected herein without the written consent of such other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that either Party may use the name of the other Party in any document . No such approval shall be required to be filed to obtain Regulatory Approval republish a disclosure previously made or to comply with applicable laws, rules or regulationsotherwise in the public domain.
Appears in 5 contracts
Sources: License Agreement (Oscient Pharmaceuticals Corp), License Agreement (Oscient Pharmaceuticals Corp), License Agreement (Cornerstone Therapeutics Inc)
Use of Names. Except as otherwise provided in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the consent of such other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that either Party may use the name of the other Party in any document required to be filed to obtain Regulatory Approval or to comply with applicable laws, rules or regulations.
Appears in 5 contracts
Sources: License and Supply Agreement, Assignment and Termination Agreement (Indevus Pharmaceuticals Inc), License and Supply Agreement (Indevus Pharmaceuticals Inc)
Use of Names. Except as otherwise provided in this Agreement, neither Neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that either Party may use the name of the other Party in any document required to be filed to obtain Regulatory Approval regulatory approval or to comply with applicable laws, rules or regulations.
Appears in 4 contracts
Sources: Exclusive License Agreement (Quatrx Pharmaceuticals Co), Exclusive License Agreement (Quatrx Pharmaceuticals Co), Exclusive License Agreement (Quatrx Pharmaceuticals Co)
Use of Names. Except as otherwise provided in this Agreement, neither Neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld or delayed; provided, provided however, that either Party may use the name of the other Party in any document required to be filed to obtain with any Regulatory Approval or to comply with applicable laws, rules or regulationsAuthority.
Appears in 4 contracts
Sources: License and Supply Agreement (Ruthigen, Inc.), License and Supply Agreement (Oculus Innovative Sciences, Inc.), License and Supply Agreement (Ruthigen, Inc.)
Use of Names. Except as otherwise provided in required by law or by the terms of this AgreementAgreement or as mutually agreed upon by the Parties, neither Party shall make any use of the name of the other Party in relation to this transaction in any public announcementadvertising or promotional material, press release or other public document otherwise, without the prior written consent of such the other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that either Party may use the name of the other Party in any document required to be filed to obtain Regulatory Approval or to comply with applicable laws, rules or regulationswithheld.
Appears in 3 contracts
Sources: Supply Agreement (Vivus Inc), Manufacturing and Supply Agreement (Vivus Inc), Commercial Supply Agreement (Vivus Inc)
Use of Names. Except as otherwise provided in this Agreement, Subject to Sections 9.1.3 and 9.2 neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the prior, written consent of such other Party, which consent shall not be unreasonably withheld or delayedwithheld; provided, however, that either Party may use the name of the other Party in any document filed with any Regulatory Authority, including FDA, or with the Securities and Exchange Commission or otherwise as required to be filed to obtain Regulatory Approval or to comply with by applicable laws, rules or regulationsLaw.
Appears in 3 contracts
Sources: Commercialization and License Agreement (Aptalis Holdings Inc.), Commercialization and License Agreement (Aptalis Pharma Inc), Commercialization and License Agreement (Aptalis Pharma Inc)
Use of Names. Except as otherwise provided in this Agreement, neither Neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the prior written consent of such other Party, which consent shall not be unreasonably withheld or delayedwithheld; provided, however, that either Party may use the name of the other Party in any document required to be filed to obtain Regulatory Approval with any regulatory agency or to comply with applicable lawsauthority, rules or regulationsincluding the FDA, EMEA and the U.S. Securities and Exchange Commission.
Appears in 2 contracts
Sources: Manufacture and Supply Agreement (Innocoll AG), Manufacture and Supply Agreement (Innocoll GmbH)
Use of Names. Except as otherwise provided in this Agreement, neither Neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the prior written consent of such other Party, which consent shall not be unreasonably withheld or delayedwithheld; provided, however, that either Party may use the name of the other Party in any document required to be filed to obtain Regulatory Approval with any regulatory agency or to comply with applicable lawsauthority, rules or regulationsincluding the FDA and the Securities and Exchange Commission.
Appears in 2 contracts
Sources: License and Distribution Agreement (Novadel Pharma Inc), License and Distribution Agreement (Novadel Pharma Inc)
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that either Party may use the name of the other Party in any document required to be filed to obtain Regulatory Approval or to comply with applicable laws, rules or regulationswithheld.
Appears in 2 contracts
Sources: Distribution Agreement (Neuronetics, Inc.), Distribution Agreement (Neuronetics, Inc.)
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld or delayedwithheld; provided, however, that subject to Section 12.2, either Party may use the name of the other Party in any document required to be filed to obtain with any Regulatory Approval Authority or to comply with applicable lawsGovernmental Authority, rules or regulationsincluding the Securities and Exchange Commission.
Appears in 2 contracts
Sources: License, Development and Commercialization Agreement (MEI Pharma, Inc.), License, Development and Commercialization Agreement (MEI Pharma, Inc.)
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld or delayedwithheld; provided, however, that subject to Section 12.5, either Party may use the name of the other Party in any document required to be filed to obtain with any Regulatory Approval Authority or to comply with applicable lawsGovernmental Authority, rules or regulationsincluding the FDA, EMEA and the Securities and Exchange Commission.
Appears in 2 contracts
Sources: Development, Commercialization and Supply Agreement (Auxilium Pharmaceuticals Inc), Development, Commercialization and Supply Agreement (Auxilium Pharmaceuticals Inc)
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld withheld, conditioned or delayed; provided, however, that subject to Section 5.6, either Party may use the name of the other Party in any document required to be filed to obtain with any Regulatory Approval Authority or to comply with applicable lawsGovernmental Authority, rules or regulationsincluding the FDA, EMA and the Securities and Exchange Commission.
Appears in 1 contract
Sources: Collaboration and Option Agreement (Aptevo Therapeutics Inc.)
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that either Party may use the name of the other Party in any document required to be filed to obtain Regulatory Approval with any regulatory agency or to comply with applicable lawsauthority, rules or regulationsincluding the FDA and the Securities and Exchange Commission.
Appears in 1 contract
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld withheld, conditioned or delayed; provided, however, that subject to Section 11.4, either Party may use the name of the other Party in any document required to be filed to obtain with any Regulatory Approval Authority or to comply with applicable lawsGovernmental Authority, rules or regulationsincluding the Securities and Exchange Commission.
Appears in 1 contract
Sources: License, Development and Commercialization Agreement (Ignyta, Inc.)
Use of Names. Except as otherwise provided in this Agreement, neither ------------- Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the consent of such other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that either Party may use the name of the other Party in any document required to be filed to obtain Regulatory Approval or to comply with applicable laws, rules or regulations.
Appears in 1 contract
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall will use the name of the other Party in relation to this transaction in any public announcement, press release release, or other public document without the written consent of such other Party, which consent shall will not be unreasonably withheld or delayedwithheld; provided, however, that subject to Section 10.5 (Publicity), either Party may use the name of the other Party in any document required to be filed to obtain Regulatory Approval or to comply with applicable lawsany Governmental Authority, rules or regulationsincluding the U.S. Securities and Exchange Commission.
Appears in 1 contract
Use of Names. Except as otherwise provided expressly set forth in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld or delayedwithheld; providedprovided that, howeversubject to Sections 9.3 and 9.7, that either Party may use the name of the other Party in any document required to be filed to obtain with any Regulatory Approval Authority or to comply with applicable lawsGovernmental Authority, rules or regulationsincluding the FDA, EMA and the SEC.
Appears in 1 contract
Sources: License and Collaboration Agreement (Theravance Biopharma, Inc.)
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld or delayedwithheld; provided, however, that that, subject to Section 11.5, either Party may use the name of the other Party in any document required to be filed to obtain with any Regulatory Approval Authority or to comply with applicable lawsGovernmental Authority, rules or regulationsincluding the FDA and the Securities and Exchange Commission.
Appears in 1 contract
Use of Names. Except as otherwise provided in required by law or by the terms of this AgreementAgreement or mutually agreed upon by the Parties, neither Party shall make any use of the name of the other Party in relation or any trade name or trademark belonging to this transaction the other Party in any public announcement, press release advertising or other public document promotional material without the prior consent of such the other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that either Party may use the name of the other Party in any document required to be filed to obtain Regulatory Approval or to comply with applicable laws, rules or regulationswithheld.
Appears in 1 contract
Use of Names. Except as otherwise provided in required by law or by the terms of this AgreementSupply Agreement or mutually agreed upon by the Parties, neither Party shall make any use of the name of the other Party in relation to this transaction in any public announcementadvertising or promotional material, press release or other public document otherwise, without the prior written consent of such the other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that either Party may use the name of the other Party in any document required to be filed to obtain Regulatory Approval or to comply with applicable laws, rules or regulationswithheld.
Appears in 1 contract
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld or delayedwithheld; provided, however, that subject to Section 12.3, either Party may use the name of the other Party in any document required to be filed to obtain with any Regulatory Approval Authority or to comply with applicable lawsGovernmental Authority, including the Securities and Exchange Commission or the rules or regulationsof any securities exchange.
Appears in 1 contract
Sources: License, Development and Commercialization Agreement (Aimmune Therapeutics, Inc.)
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall will use the name of the other Party in relation to this transaction in any public announcement, press release release, or other public document without the written consent of such other Party, which consent shall will not be unreasonably withheld or delayedwithheld; provided, however, that subject to Section 9.5 (Publicity), either Party may use the name of the other Party in any document required to be filed to obtain Regulatory Approval or to comply with applicable lawsany Governmental Authority, rules or regulationsincluding the U.S. Securities and Exchange Commission.
Appears in 1 contract
Use of Names. Except as otherwise provided in this AgreementSubject to Section 7.2, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the prior written consent of such other Party, which consent shall not be unreasonably withheld withheld, delayed, or delayedconditioned; provided, however, that either Party may use the name of the other Party in any document required to be filed to obtain Regulatory Approval or to comply with applicable lawsany Governmental Authority, rules or regulationsincluding the FDA, the U.S. Securities and Exchange Commission, and the TSX.
Appears in 1 contract
Sources: Marketing, Distribution and Supply Agreement (Biovail Corp International)
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the prior written consent of such other Party, which consent shall not be unreasonably withheld or delayedwithheld; provided, however, that subject to Section 10.5, either Party may use the name of the other Party in any document required to be filed to obtain with any Regulatory Approval or to comply with applicable lawsAuthority, rules or regulationsincluding the FDA, EMA, PMDA and the U.S. Securities and Exchange Commission.
Appears in 1 contract
Sources: License and Development Agreement (Radius Health, Inc.)
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld or delayedwithheld; provided, however, that subject to Section 12.5, either Party may use the name of the other Party in any document required to be filed to obtain Regulatory Approval with any regulatory agency or to comply with applicable lawsGovernmental Authority, rules or regulationsincluding the FDA, NMPA and the Securities and Exchange Commission.
Appears in 1 contract
Sources: License and Collaboration Agreement (Onconova Therapeutics, Inc.)
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld or delayedwithheld; provided, however, that either Party may use the name of the other Party in any document required to be filed to obtain with any Regulatory Approval Authority or to comply with applicable lawsGovernmental Authority, rules or regulationsincluding the FDA, EMEA and the Securities and Exchange Commission.
Appears in 1 contract
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall will use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall will not be unreasonably conditioned, withheld or delayed; provided, however, that subject to Section 12.4 (Publications), either Party may use the name of the other Party in any document required to be filed to obtain with any Regulatory Approval Authority or to comply with applicable lawsGovernmental Authority, rules or regulationsincluding the Securities and Exchange Commission.
Appears in 1 contract
Sources: License, Development and Commercialization Agreement (Agenus Inc)
Use of Names. Except as otherwise provided in this Agreement, neither Neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the prior written consent of such other Party, which consent shall not be unreasonably withheld or delayedwithheld; provided, however, that either Party may use the name of the other Party in any document required to be filed to obtain Regulatory Approval with any regulatory agency or to comply with applicable lawsauthority, rules or regulationsincluding the FEMA, FDA and the U.S. Securities and Exchange Commission.
Appears in 1 contract
Sources: License and Commercialization Agreement (Redpoint Bio CORP)
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld or delayedwithheld; provided, however, that subject to Section 13.5, either Party may use the name of the other Party in any document required to be filed to obtain Regulatory Approval with any regulatory agency or to comply with applicable lawsGovernmental Authority, rules or regulationsincluding the FDA, EMEA and the Securities and Exchange Commission.
Appears in 1 contract
Sources: License and Collaboration Agreement (Immunomedics Inc)
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld withheld, conditioned or delayed; provided, however, that subject to Section 12.5, either Party may use the name of the other Party in any document required to be filed to obtain with any Regulatory Approval Authority or to comply with applicable lawsGovernmental Authority, rules or regulationsincluding the Securities and Exchange Commission.
Appears in 1 contract
Sources: Development, Commercialization and Supply Agreement (Amarin Corp Plc\uk)
Use of Names. Except as otherwise expressly provided for in this Agreement, neither Party shall party will use the name or logo (or any variation thereof) or any trade name or service ▇▇▇▇ of the other Party in relation to this transaction in any public announcement, press release or other public document party without the consent of such other Partyparty’s prior written consent, which consent shall not may be unreasonably withheld or delayed; provided, however, that either Party may use the name of the other Party in any document required to be filed to obtain Regulatory Approval or to comply with applicable laws, rules or regulationswithheld.
Appears in 1 contract
Sources: Fund Services Agreement (Seligman Lasalle Real Estate Fund Series Inc)
Use of Names. Except as otherwise provided in this AgreementSection 8.2 or pursuant to Section 4.4.2, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld withheld, conditioned or delayed; provided, however, that either Party may use the name of the other Party in any document required filed with any governmental authority, in all cases subject to be filed such Party giving complete and appropriate attribution to obtain Regulatory Approval or to comply with applicable laws, rules or regulationsthe other Party’s role(s) in the project contemplated in this Agreement.
Appears in 1 contract
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that either Party may use the name of the other Party in any document required to be filed to obtain Regulatory Approval with any regulatory agency or to comply with applicable lawsGovernmental Authority, rules or regulationsincluding the FDA and the Securities and Exchange Commission.
Appears in 1 contract
Sources: Supply and Employee Agreement (Kos Pharmaceuticals Inc)
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld or delayedwithheld; provided, however, that subject to Section 12.5, either Party may use the name of the other Party in any document required to be filed to obtain with any Regulatory Approval Authority or to comply with applicable lawsGovernmental Authority, rules or regulationsincluding the FDA and the Securities and Exchange Commission.
Appears in 1 contract
Sources: License, Development and Commercialization Agreement (Brickell Biotech, Inc.)
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld or delayedwithheld; provided, however, that subject to Section 12.5, either Party may use the name of the other Party in any document filed with or required to be filed to obtain released by any Regulatory Approval Authority or to comply with applicable lawsGovernmental Authority, rules or regulationsincluding the Securities and Exchange Commission.
Appears in 1 contract
Sources: Collaboration Agreement (Auxilium Pharmaceuticals Inc)
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld withheld, conditioned or delayed; provided, however, that subject to Section 11.6, either Party may use the name of the other Party in any document required to be filed to obtain with any Regulatory Approval Authority or to comply with applicable lawsGovernmental Authority, rules or regulationsincluding the FDA, EMA and the SEC.
Appears in 1 contract
Use of Names. Except as otherwise provided expressly set forth in this Agreement, neither Party party shall use the name or marks of the other Party in relation to this transaction party in any advertising or public announcement, press release or other public document communication without the prior written consent of such other Partyparty, which consent shall not be unreasonably withheld or delayed; delayed provided, however, that either Party party may use disclose to third parties the name Formulary status of the other Party in any document required to be filed to obtain Regulatory Approval or to comply with applicable laws, rules or regulationsProduct.
Appears in 1 contract
Sources: Promotional Rights Agreement (Emmaus Holdings, Inc.)
Use of Names. Except as otherwise provided set forth in this Agreement, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld or delayedwithheld; provided, however, that subject to Section 12.5, either Party may use the name of the other Party in any document required to be filed to obtain with any Regulatory Approval Authority or to comply with Governmental Authority, including the Securities and Exchange Commission and any applicable laws, rules or regulationssecurities exchanges.
Appears in 1 contract
Sources: Development, Commercialization and Supply Agreement (Vascular Biogenics Ltd.)
Use of Names. Except as otherwise provided in this AgreementSection 6.2 or pursuant to Section 3.5.2, neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld withheld, conditioned or delayed; provided, however, that either Party may use the name of the other Party in any document required filed with any governmental authority, in all cases subject to be filed such Party giving complete and appropriate attribution to obtain Regulatory Approval or to comply with applicable laws, rules or regulationsthe other Party’s role(s) in the project contemplated in this Agreement.
Appears in 1 contract
Sources: Licensing Agreement (Satsuma Pharmaceuticals, Inc.)
Use of Names. Except as otherwise provided Neither Party will use or refer to this Agreement in this Agreementany promotional activity, neither Party shall or use the name marks of the other Party, without express prior written permission of the other Party. Both Parties shall refrain from making any public announcement or disclosure of this Agreement and its terms without the prior written consent of the other Party in relation to this transaction in any public announcement, press release or other public document without the consent of such other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that either Party may use the name of the other Party in any document except as required to be filed to obtain Regulatory Approval or to comply with applicable laws, rules or regulationsby law.
Appears in 1 contract
Use of Names. Except as otherwise provided in this Agreement, neither Neither Party shall use the name of the other Party in relation to this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that either Party may use the name of the other Party in any document required to be filed to obtain with any Regulatory Approval Authority or other authority to comply with applicable lawslegal or regulatory requirements, rules or regulationsincluding the FDA, the EMA and the Securities and Exchange Commission.
Appears in 1 contract
Sources: Research Collaboration and License Agreement (Evotec SE)